Commencement of Manufacturing and Sales of F-hiSIEC, Human iPS Cell-Derived Intestinal Epithelial Cells
First written in FY2020-Q2. 3 of 6 entries say "Restated". Latest entry: FY2022-Q3.
No other company in this theme has enough history to compare yet.
- FY2022-Q3DroppedAnnual report
「The Company ended sales of FUJIFILM's human iPS cell-derived intestinal epithelial cells, F-hiSIEC™, at the end of December.」
The Company's previous manufacturing and sales of F-hiSIEC ended at the end of December 2021. - FY2022-Q1RestatedAnnual report
「In addition, sales of the human iPS cell-derived intestinal epithelial cells F-hiSIEC™ also grew steadily.」
The Company continues to disclose sales growth for F-hiSIEC since manufacturing and sales began. - FY2021-Q2RestatedAnnual report
「In addition, since September 2019, the Company has manufactured and sold FUJIFILM's human iPS cell-derived intestinal epithelial cells, F-hiSIEC™, and sales have continued to grow steadily.」
The Company continues to disclose steady sales growth for F-hiSIEC since manufacturing and sales began. - FY2020RestatedAnnual report
「The product has received considerable interest from pharmaceutical companies and food manufacturers, with many inquiries, and got off to a strong start. The Company will continue sales activities in cooperation with FUJIFILM to increase awareness of the product and will work to further increase sales.」
The Company reported F-hiSIEC's strong start and the many inquiries received after manufacturing and sales began, and continues joint sales activities with FUJIFILM. - FY2020-Q3AdvancedAnnual report
「In September 2019, the Company also began manufacturing and selling FUJIFILM's new product, F-hiSIEC™ (エフ－ハイシーク), human iPS cell-derived intestinal epithelial cells. The product has received considerable interest from pharmaceutical companies and food manufacturers, with many inquiries, and got off to a strong start. The Company will continue sales activities in cooperation with FUJIFILM to increase awareness of the product and will work to further increase sales.」
F-hiSIEC got off to a strong start after manufacturing and sales began in September 2019, with many inquiries received. Joint sales activities with FUJIFILM will continue. - FY2020-Q2First statedAnnual report
「In September 2019, the Company also began manufacturing and selling FUJIFILM's new product, F-hiSIEC™ (エフ－ハイシーク), human iPS cell-derived intestinal epithelial cells. The product is offered as an innovative drug discovery support tool that enables highly accurate evaluation of drug absorption using iPS cells, and the Company aims to expand the business.」
For FUJIFILM's human iPS cell-derived intestinal epithelial cells, F-hiSIEC, the Company began manufacturing and sales in September 2019 and first presented measures to expand its research and development support business as a drug discovery support tool.